Press Releases

Fifth Annual Emerging Company Forum Being Held In San Francisco In Conjunction With The JP Morgan Annual Healthcare Conference BETHESDA, MD, January 10, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it will be making a presentation today at 10:45 am (PST) in the Windsor Room of the Sir Francis Drake Hotel as part of the fifth annual OneMedForum SF 2012 Conference for emerging biotech companies held over... Read More

Projections Met for Third Consecutive Quarter BETHESDA, MD, January 9, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it successfully met its projection that it would have 25 trial sites open and recruiting by the end of Q4, 2011, in its ongoing clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company likewise met or exceeded the... Read More

Confirmed by Legal Opinions from Nationally Recognized Law Firms Bethesda, Maryland, December 19, 2011 — After obtaining confirmatory opinions from multiple experts in patent law, Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today reaffirms that its lead program, applying DCVax®-L for treatment of brain cancer, continues to have clear freedom to operate with respect to US Patent 7,939,090 (the ‘090 patent), recently issued to... Read More

Removes $31.5 Million Of Liabilities Bethesda, Maryland, December 2, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) announced today that it has implemented a major clean-up of its balance sheet, removing $31.5 million of liabilities through settlement, retirement and conversion. This restructuring reduces the Company’s liabilities from $48 million at the end of the third quarter to $16.5 million. Only about $2.3... Read More

$2.4 Million Immediate Funding and Agreement to Purchase First $3 Million of New Shares Under Pending Equity Facility BETHESDA, MD, November 17, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) today announced $2.4 million in new funding under favorable loan terms, as well as an agreement to purchase the first $3 million in shares of common stock under the previously announced agreement for an equity facility of up to... Read More